Immunotherapy plus standard treatment for high-risk osteosarcoma in kids and young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, randomized trial enrolls patients aged 5–30 with high-risk osteosarcoma. It compares an experimental arm receiving mifamurtide with standard chemotherapy to a control arm receiving standard treatment that includes sorafenib. Researchers will collect tumor tissue and blood samples for molecular testing, track disease progression with routine imaging and organ assessments, and analyze how genetic findings relate to treatment outcomes. The study uses intention-to-treat analysis to compare efficacy and safety between groups.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Part I:

1. Age ≥ 5 to ≤ 30 years at the time of qualification.
2. Histopathologically confirmed osteosarcoma based on previous diagnostic tests.
3. Provision of written, informed consent to participate in the study, including treatment with mifamurtide and sorafenib, in accordance with current legal regulations, prior to the initiation of any study procedures.

Part II:

1. Participants of the Part I classified as high-risk.
2. Expected survival of at least 12 weeks from the time of signing informed consent.
3. Patient deemed capable of receiving systemic treatment.
4. Patient able to swallow tablets.
5. Disease in complete remission or stable disease per WHO criteria before randomization.
6. Major surgery performed ≥ 2 weeks and radiotherapy ≥ 4 weeks before inclusion in the mifamurtide group.
7. Recovery from adverse effects of prior surgery and/or radiotherapy.
8. Signed informed consent to participate in the study (including mifamurtide and sorafenib treatment) in accordance with applicable legal regulations.
9. Agreement to use effective contraception throughout the study period and for at least one year after discontinuing treatment for patients of reproductive age.

Exclusion Criteria:

1. Failure to meet any of the inclusion criteria.
2. Previous treatment with mifamurtide.
3. Hypersensitivity to the investigational drug or any of its components (including mifamurtide and sorafenib).
4. Concurrent treatment with drugs that may interact with mifamurtide, sorafenib, or other cytostatics.
5. Persistent toxicity from prior therapy that precludes treatment with mifamurtide or sorafenib.
6. Significant cardiac conduction abnormalities, including a known family history of long QT syndrome or a corrected QT interval (QTc) \> 480 ms.
7. Symptoms of congestive heart failure or a left ventricular ejection fraction \< 50%.
8. Need or probable need for corticosteroids at doses \> 10 mg of prednisone (or equivalent) daily or other immunosuppressive drugs.
9. Uncontrolled blood pressure.
10. Arterial or venous thromboembolic events, such as stroke (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months before the first administration of the investigational drug.
11. Active hepatitis B or C or chronic hepatitis B or C requiring antiviral therapy.
12. Any bleeding or hemorrhagic event ≥ CTCAE v5 grade 3 within 4 weeks before the first administration of the investigational drug.
13. Diagnosis of other malignancies prior to study entry.
14. Pregnancy planning, current pregnancy, or breastfeeding.
15. Other acute or persistent disorders, behaviors, or abnormal laboratory results that may increase the risk associated with participation in this clinical study or receiving the investigational drug, may impact study results interpretation, or, in the investigator's opinion, disqualify the patient from study participation

Where it's running

• Mother and Child Institute
  Warsaw, Mazovian, Poland Recruiting

Study contacts

• Study coordinator: Anna Raciborska, Prof.
• Email: klinika.onkologii@imid.med.pl
• Phone: +48 22 32 77 205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• 68Ga-B7-H3 Nanobody PET Imaging in Osteosarcoma

  This study tests a new gallium-68 labeled B7-H3 nanobody to see if it can image osteosarcoma tumors more clearly.

  Recruiting Early Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07774533

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Neoantigen Vaccine SarVac With Tumor-Specific Lymphocytes Plus PD-1 Blocker for Advanced Sarcoma

  This trial tests a personalized cancer vaccine called SarVac, given with a PD-1 blocker, and possibly tumor-specific lymphocytes, to see if it is safe and can help people with advanced soft tissue or bone sarcoma.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07648069

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Cryoablation plus anti-PD-1 therapy for advanced soft tissue sarcoma

  This study tests whether freezing tumors and giving camrelizumab can help people with advanced soft tissue sarcoma after standard treatments have failed.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07602049

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.